Digene Still Expecting HPV DNA Pap Test Primary Screen Approval By 2003
This article was originally published in The Gray Sheet
Executive Summary
Digene will re-analyze pivotal study data to demonstrate clinical utility of its HPV DNA Pap test as a primary screen for cervical cancer in response to an FDA request for additional information
You may also be interested in...
Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002
Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review
Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002
Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review
Ventana Preparing HPV Test Submission, Will Co-Market With ChromaVision
Ventana Medical Systems plans to seek premarket approval for its Inform human papilloma virus (HPV) test by year-end as a follow-up screen for women whose Pap results show atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intra-epithelial lesions (LSIL)